Zencurix Obtains MFDS Manufacturing Approval for Thyroid Cancer Mutation In Vitro Diagnostic Kit
[Asia Economy Reporter Lee Gwan-joo] GenCurix announced on the 7th that it has obtained manufacturing approval from the Ministry of Food and Drug Safety for the thyroid cancer mutation in vitro diagnostic kit 'Droplex BRAF Mutation Test.'
Hot Picks Today
!["Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"](https://cwcontent.asiae.co.kr/asiaresize/93/2026081215431278523_1786516992.gif)
"Despite Complaints About Sweat, She Straps On a 15kg Bag and Pushes Through the Deadly Heatwave [Sociology of Heatwaves] ①"
- Thought It Was a Patriot’s Calligraphy, But Possibly a Pro-Japanese Collaborator’s? National Museum Issues Apology
- "If You Don't Buy Now, You'll Be Too Late"... Office Workers Rush for Golden Holiday as Flight and Hotel Reservations Heat Up
- Salt Farms: Five Major Insurance Enrollment Rate at Only 8%... "Working Conditions Very Vulnerable"
- "Controversy Over Female YouTuber Who Filmed in Mixed-Gender Bath Despite Knowing Filming Was Prohibited"
This kit is an in vitro diagnostic medical device that detects the presence of mutations in the BRAF gene 'Codon 600' from DNA derived from tissues of patients with papillary thyroid carcinoma (PTC) using digital PCR technology.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
